Yann Mazabraud
Known title: EVP, Head of InternationalCIK: 0001774702
Associated companies
Transaction History
| RYTM | ▲ Buy | Option Exercise | 46,625 | $317K | 8/12/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 2,300 | $257K | 8/12/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,000 | $113K | 8/12/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,605 | $413K | 8/12/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 17,319 | $2.0M | 8/12/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 14,568 | $1.7M | 8/12/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 18,208 | $2.1M | 8/12/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 12,875 | — | 4/1/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 10,000 | — | 2/14/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 5,500 | — | 2/1/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 6,745 | $439K | 4/29/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 11,405 | — | 4/15/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 10,375 | — | 4/14/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 8,438 | $509K | 4/8/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 9,312 | $573K | 4/8/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 75,000 | $1.7M | 3/14/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 55,803 | $2.9M | 3/14/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 19,197 | $975K | 3/14/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 5,500 | — | 2/16/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 10,375 | — | 4/14/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 16,000 | $628K | 3/19/2024 | View on chart |
| RYTM | ▲ Buy | Grant | 33,750 | $0 | 2/16/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 957 | $48K | 2/13/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,594 | $82K | 2/12/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,031 | — | 2/11/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,438 | — | 2/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,177 | $32K | 2/14/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,031 | — | 2/11/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,548 | $43K | 2/9/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,438 | — | 2/9/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 934 | $6K | 2/15/2022 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,032 | — | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.